QIAGEN is the world's leading independent provider of molecular technologies for personalized healthcare, currently offering more than 30 commercial assays including tests for the biomarkers KRAS, EGFR, BRAF and PI3K. QIAGEN is expanding its presence in the personalized healthcare field through regulatory submissions in the U.S., Japan and other markets as well as through targeted acquisitions. QIAGEN has already accumulated a deep portfolio of proprietary markers that have the potential to play a significant role in a broad range of personalized healthcare applications. QIAGEN is considered a leading company in terms of research and development partnerships for companion diagnostics with pharmaceutical companies.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. As o
|SOURCE QIAGEN N.V.|
Copyright©2010 PR Newswire.
All rights reserved